German Merck signs collaboration deal for PARP inhibitor

Merck KGaA (MKGAF) inks a second collaboration deal with Beijing-based BeiGene.

The new deal is a licensing, development, and commercialization agreement for BeiGene-290, a preclinical PARP inhibitor.

The terms of the agreement call for German Merck to take on the development and commercialization responsibilities for '290 outside of China.

Milestone payments to BeiGene could reach $232M.

BeiGene also received an undisclosed upfront payment. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs